CTLA4 and rheumatoid arthritis: Recent advances in biological disease-modifying anti-rheumatic drugs (bDMARDs) have revolutionized the management of RA [1], with four main groups available: anti-CD20 antibody rituximab, cytotoxic T lymphocyte-associated antigen 4‐immunoglobulin (CTLA4-Ig) abatacept, interleukin (IL)-6 receptor inhibitors (such as tocilizumab and sarilumab), and tumor necrosis factor inhibitors (TNFi) which include infliximab, adalimumab, golimumab, certolizumab, and etanercept.